

INVITATION TO SUBSCRIBE FOR UNITS IN

The logo for Curasight, featuring the word "curasight" in a lowercase, sans-serif font. The "c" is stylized with a blue swoosh that loops around it and extends to the left.

16-30 SEPTEMBER 2024

**IMPORTANT INFORMATION**

This information folder constitutes marketing and is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council. The invitation to subscribe for units in Curasight A/S ('Curasight' or the 'Company') is only made through the prospectus published in September 2024, which is available on Curasight's website www.curasight.com. Investors are advised to read the prospectus in its entirety before making an investment decision. This information brochure may not be distributed, published in or into the United States, Australia, Japan, Canada, New Zealand, South Africa, the United Kingdom, Hong Kong, Russia, Belarus, Switzerland or Singapore. The information brochure may not be sent to persons in these countries or any other jurisdiction to which it is unlawful to deliver unit rights, BTUs or shares, except in accordance with applicable law and provided that it does not require additional prospectuses, registration or other measures in addition to those required by Danish law. Unless otherwise expressly stated in the prospectus, unit rights, BTUs or warrants may not be offered, sold, transferred or delivered, directly or indirectly, in or into any of these countries.

INVESTMENT HIGHLIGHTS

Proof-of-Concept

In recent years, the interest for radionuclide-based technology like uTREAT® has increased from the scientific community as well as from the established pharmaceutical industry. Curasight has gained proof-of-concept for its uTRACE® diagnostic technology based on the uPAR receptor (biomarker) in phase 2 trials in nine different cancer indications with a total of more than 400 patients.

Market

The interest for radionuclide-based technology like uTREAT® has increased in the recent years. The Global nuclear medicine market is expected to grow from USD 5.9 billion in 2019 to USD 35 billion in 2031. Total nuclear medicine, nuclear medicine therapy and nuclear medicine diagnostics sales is projected to grow by 19%, 35% and 7% per year between 2019 and 2031.

Nuclear medicine is the future in cancer therapy and drugmakers go nuclear, continuing push into radiopharmaceuticals. The last years, a higher activity has been noted on the acquisition front for nuclear medicine, illustrating that nuclear medicine is the future in cancer therapy. For example, Novartis has acquired Mariana Oncology for USD 1 billion and Eli Lilly bought Point Biopharma for USD 1.4 billion.

Partnership

Curasight collaborates with highly specialized partners to support its operational drug development within research and clinical contract organizations who are highly competent in the field of both diagnostic and therapeutic radiopharmaceuticals. By forming partnerships Curasight ensures access to top development manufacturing expertise and capacity and skills in conducting manufacturing of investigational medicine and clinical trials.

Currently, Curasight is focused on generating data with both uTRACE® and uTREAT® for different cancer indications. Each of these cancers offer different development opportunities and it is Curasight's aim, based on clinical data, to find experienced industrial partners on the later stages of development of uTRACE® and uTREAT® and bring both products to the market. Curasight has entered a global license- and partnership agreement for uTRACE® in prostate cancer with Curium, a leader in the field of radionuclide medicine. Estimated deal value USD 3,8 billion according to SEB.

Future

Curasight is expanding and accelerating its clinical therapeutic strategy. Curasight is looking into how to further leverage the platform to realize the vast potential of uTRACE® for diagnosing and uTREAT® for targeted radionuclide therapy in other cancer types where uPAR is also expressed.

OBJECTIVES

2024

- Q4 Last patient included part I - uTRACE® (Phase II, Prostate Cancer, Partnered project)
- Q4 Preliminary efficacy data - uTRACE® (Phase II, Prostate Cancer, Partnered project)

2025

- H1 Acceptance of CTA by EMA - uTREAT® (Phase I/IIa, Therapeutic program, First indication)
- H1 Last patient included Part II - uTRACE® (Phase II, Prostate Cancer, Partnered project)
- H1 First patient dosed, part I - uTREAT® (Phase I/IIa, Therapeutic program, First indication)
- H2 Topline results, Phase II - uTRACE® (Phase II, Prostate Cancer, Partnered project)
- H2 Preliminary efficacy data - uTREAT® (Phase I/IIa, Therapeutic program, First indication)
- H2 First patient included part II - uTREAT® (Phase I/IIa, Therapeutic program, First indication)

2026

- Acceptance of CTA by EMA and first patient included part I - uTREAT® (Phase I/IIa, Therapeutic program, Basket trial)
- Last patient included part II - uTREAT® (Phase I/IIa, Therapeutic program, First indication)

2027

- Topline results, Phase I/IIa - uTREAT® (Phase I/IIa, Therapeutic program, First indication)
- Last patient included part I and preliminary efficacy data - uTREAT® (Phase I/IIa, Therapeutic program, Basket trial)

CURASIGHT'S BUSINESS

Curasight is a clinical stage biotech company and is the pioneer behind the novel uPAR Theranostics technology. The technology minimizes irradiation of healthy tissue by combining the targeted uTREAT® radiation therapy with the precise uTRACE® diagnostics. Nine investigator-initiated phase II clinical trials with uTRACE® have been completed or are currently undertaken.

uTRACE® solution is expected to have major advantages in the future evaluation of prostate cancer because it is expected to help determine what type of treatment – and in particular if surgery is necessary. Today most prostate cancer patients having prostatectomies performed are operated unnecessarily and most of these patients (up to 70 percent) experience some degree of side effects, such as impotence. The company believes that using Curasight's product and diagnosis could improve patient management. uTRACE® is designed to provide a more accurate categorisation of a patient's tumour, supporting more tailored treatment plans and allowing identification of the necessary treatment at the right time.

uTRACE® images cancer aggressiveness and invasive potential. By imaging this, Curasight's technology can diagnose and determine which therapeutic strategy should be pursued, e.g. if the patient needs treatment (e.g. surgery such as prostatectomy and/or radiotherapy) or not. In addition, uTRACE® will be used for theranostics (principle of combined therapy and diagnostics) and precision medicine, selecting the right therapy to the right person at the right time, creating substantial benefits for both patients and the healthcare system.

utreat
THERAPEUTIC SOLUTIONS

utrace
DIAGNOSTIC SOLUTIONS

uTREAT® (Therapy)

Curasight's uTREAT® is a new type of targeted radiation therapy, targeting and irradiating the cancer cells and almost not healthy tissue. By injecting a substance that seeks all cancer cells, including the metastases that are far away from the primary tumour, this offers a more gentle and efficient therapy to each patient.

uTRACE® (Diagnostics)

Curasight's uTRACE® is a uPAR-PET imaging and diagnostics technology. It is used to find, visualise, and predict whether a cancer is aggressive or not and if so, how it should be treated. uTRACE® has been tested on over 400 patients in several cancer forms and proven to be safe and well tolerated.

uPAR Theranostics

THE OFFER IN BRIEF

Subscription period: 16-30 September 2024

Subscription price: DKK 0.01 per unit. One (1) unit consist of two (2) warrants of series TO2 and one (1) warrant of series TO3. Note that no shares are issued through the rights issue.

Issue volume: Upon full subscription, the gross proceeds from the rights issue will be DKK 12,169.07. Curasight can receive proceeds from the exercise of warrants of series TO2 and series TO3 in December 2024 and June 2025, respectively, after each of the exercise periods for the warrant series.

Warrants of series TO2 and TO3: The exercise period for TO2 runs 21 November-5 December 2024 and the exercise period for TO3 runs 4-18 June 2025. The exercise price for warrants of series TO2 and series TO3 shall amount to seventy (70) percent of the average volume-weighted price for the share during the period of 20 trading days ending two (2) banking days before each of the exercise periods begin. The exercise price for TO2 may not exceed DKK 15.55 per share, nor be less than DKK 11.50. The exercise price for TO3 may not exceed DKK 19.40 per share, nor be less than DKK 15.55. If all warrants of series TO2 are exercised at the highest price, Curasight will be provided DKK 57.3 million (before issue costs) through warrants of TO2, in December 2024. If all warrants of series TO3 are exercised at the highest price, Curasight will be provided DKK 35.7 million (before issue costs) through warrants of TO3, in June 2025.



CEO ULRICH KRASILNIKOFF COMMENTS

During the second quarter of 2024, we have continued to build on our successes from the past year. We have enrolled the first patient in our phase 2 trial with uTRACE® in prostate cancer and showed the rapid progress in our partnership with Curium, receiving the second milestone payment under this collaboration. We also announced a capital raise aimed at further strengthening the company's finances. The fundraising includes a directed share issue, a loan facility, and warrants which has initially provided DKK 27.8 million as first step, and the package is aimed to provide up to DKK 120 million, extending our cash runway well into the second half of 2025.

The fact that we have enrolled the first patient in the uTRACE® phase II trial is a pivotal moment in the collaboration between Curasight and our partner Curium. We now aim to present part I results in the fourth quarter of this year and these results will be instrumental for Curasight. Hopefully, the results will validate the body of phase II data gathered from previous investigator-initiated trials.

Through discussions with big Pharma and key opinion leaders we understand the need to be able to demonstrate clinical "proof-of-concept" for uTREAT®. Therefore, we are in the process of identifying a rapid route to pursue a single indication where we can run a relatively cost-effective small trial that can be completed in a relatively short time frame to provide this first validation of uTREAT®. As the uPAR-biomarker is cancer specific but not cancer type specific it works across cancer types. Therefore, our aim is to find a route for rapid proof of concept which we can then follow up with a larger and more complex basket study with five different indications to provide further broader evidence of the application in different cancer types.

With the significant progress we have made I look forward what the rest of 2024 can bring. We anticipate further progress in our pipeline as well as more intense discussion with different potential partners in the industry as Radionuclide Ligand Therapy (RLT) continues to be in focus as an important option within radiotherapy in cancer.

With the capital from the warrants of series TO2 and TO3 issued through the rights issue we will have funds to finance operations into the second half of 2025. We expect to have achieved a number of milestones prior to the exercise periods of series TO2 and TO3, for example we expect preliminary efficacy data on uTRACE® (Phase II, prostate cancer, which is being run under the partnership agreement with Curium) and acceptance of Clinical Trial Application by EMA for uTREAT®, in a phase I/IIa trial in the first indication. We also expect to have dosed the first patient with uTREAT®, in this indication, providing proof-of-concept in relation to uTREAT®.

I am confident in our plans and feel strongly for the path forward. I hope that you as a shareholder will continue believing in the work, we do at Curasight and see the bright future as we see it. We invite you to be a part of this rights issue, through which you can subscribe for units containing warrants with potential to bring the Company capital in Q4 this year and Q2 next year.

Ulrich Krasilnikoff, CEO

TERMS AND CONDITIONS IN SHORT

Pre-emptive right

Each shareholder registered in the Company's share register kept by VP Securities on the record date 13 September 2024 has received one (1) pre-emptive right for each existing share held. Seventeen (17) pre-emptive rights entitle the holder to subscribe for one (1) unit. Each unit comprises of two (2) warrants of series TO2 and one (1) warrant of series TO3.

Subscription price

The units are offered at the subscription price of DKK 0.01 per unit (excluding fees, if any, from the investor's own custodian bank or brokers).

Subscription period

The subscription period runs from 16 September 2024 until 30 September 2024.

Trading in unit rights

The pre-emptive unit rights are traded on Spotlight Stock Market between 12 September 2024 and 26 September 2024.

Allocation of units

Allocation of units will be decided by Curasight's Board of Directors, with the following allocation principles:

- Subscription with support of pre-emptive unit right
- Subscription without support of pre-emptive unit right
- Guarantors (potential)
- Pre-subscriber (potential)

Plan of distribution and allotment and process for notifying applicants

The units may be subscribed for by the existing shareholders of the Company according to the pre-emptive rights allocated. Units which have not been subscribed for by the existing shareholders before the expiry of the subscription period will be cancelled. The subscribers will be notified on the number of units allotted, by their own bank.

Payments and delivery of the units

Upon exercise of the pre-emptive rights, the holder must pay an amount equal to the subscription price multiplied by the number of units subscribed for. Payment for the units shall be made in DKK and shall be made upon subscription against registration of the units in the transferee's account with VP Securities no later than 30 September 2024 at 5:00 p.m. Holders of pre-emptive unit rights shall adhere to the account agreement with their own Danish custodian institution or other financial intermediary, through which they hold existing shares. Financial intermediaries through which a holder holds pre-emptive rights may require payment on an earlier date. As soon as the rights issue has been registered, BTUs will be converted into warrants.

Minimum and maximum subscription amounts

In connection with the offering, the minimum number of new units that a holder of pre-emptive rights may subscribe

for will be one (1) unit, requiring the exercise of seventeen (17) pre-emptive unit rights and the payment of the Subscription Price. The number of new units that a holder of pre-emptive rights may subscribe for is not capped. However, the number is limited to the number of units that may be subscribed for through the exercise of the pre-emptive rights held or acquired. The minimum number of units that investor who do not hold any pre-emptive rights may subscribe for will be one (1) unit and the maximum number of units is not capped.

Subscription for remaining units

The existing shareholders can subscribe for any remaining units not subscribed for with support from pre-emptive rights. Such remaining units will be subscribed for to the same terms, including dates, as for those subscribing using pre-emptive rights. Subscription shall be made on a subscription form, which is available on the Company's website (www.curasight.com), Sedermera's website (www.sedermera.se) and Nordic Issuing's website (www.nordic-issuing.se). The subscription shall be filled out and submitted to the account holders own bank according to their respective instructions.

In case of oversubscription of remaining units in connection with the offering, the allocation of such remaining units will be determined according to allocation principles made by the Board of Directors, and this can thus result in a reduction in any shareholder's subscription made without the support of pre-emptive rights.

Payments and delivery for remaining units

Upon subscription of the remaining units, if any, the holder must pay an amount equal to the Subscription Price multiplied by the number of new units allocated. Payment for remaining units will be made via a delivery versus payment transfer through the subscriber's own bank and will be withdrawn from the account by the subscriber's own account holding bank or broker.

Trading in paid subscribed units ("BTU")

Trading in BTU with ISIN code DK0063183041 will take place on Spotlight Stock Market from 16 September 2024 until after the Danish Business Authority has registered the rights issue and BTU are converted to warrants of series TO2 and TO3.

Announcement of the results of the offering

The results of the rights issue will be communicated in a company announcement expected to be published 3 October 2024, or as soon as possible after the subscription period ends.

Withdrawal or suspension of the offering

The offering may be withdrawn by the Company subject to certain conditions before registration of the updated Articles of Association in connection with the issuance of the TO2 and TO3 warrants pertaining to the units with the Danish Business Authority. If the offering is withdrawn, any exercise of pre-emptive rights that has already taken place will be cancelled automatically.

The Company is entitled to withdraw the offer (a) if the Company decides not to pursue with the offering (b) the registration of the warrants is refused by the Danish Business Authority.

The Company is not liable for any losses that investors may suffer as a result of withdrawal of the offering including but not limited to, any transaction costs or lost interest. A withdrawal of the offering will be announced as a company announcement through a press release.

The Company is not authorized to close the offer on an earlier date than the last subscription date.

Procedure for the exercise of and trading in pre-emptive rights

The pre-emptive rights have been approved for trading and admission to trading on Spotlight Stock Market under the ISIN code DK0063183124 and will be traded in the ISIN code under the symbol "CURAS UR". Holders of pre-emptive rights wishing to subscribe for units must do so through their own custodian institution or financial intermediary, in accordance with the rules of such institution. The deadline for notification of exercise depends on the holder's agreement with, and the rules and procedures of, the relevant custodian institution or other financial intermediary and may be earlier than the end of the Subscription Period. Once a holder has exercised its pre-emptive rights, the exercise may not be revoked or modified. During the Rights Trading Period, holders of pre-emptive rights who do not wish to exercise their pre-emptive rights to subscribe for units may sell their pre-emptive rights on Spotlight Stock Market, and a purchaser may use the acquired pre-emptive rights to subscribe for units. Holders wishing to sell their pre-emptive rights should instruct their custodian institution or other financial intermediary accordingly.

Jurisdictions in which the offering will be announced and restrictions applicable to the offering

The offer is only directed at investors residing in Denmark and Sweden. As such, the offering is exclusively targeted at investors in Denmark and Sweden. The distribution of this Prospectus and the offering is restricted by law in certain jurisdictions, and this Prospectus may not be used for the purpose of, or in connection with, any offer or solicitation by anyone in any jurisdiction in which such offer or solicitation is not authorized or to any person to whom it is unlawful to make such offer or solicitation.

Withdrawal of applications of subscription

Instructions to exercise pre-emptive rights or subscriptions of remaining units related to the new units are irrevocable.

Completion of the offering

The offering will only be completed if and when the units subscribed for are issued by the Company upon registration with the Danish Business Authority, which is expected to take place on or around 10 October 2024. A company announcement concerning the results of the offering is expected to be disclosed around 3 October 2024.

Financial advisor, issuing and settlement agent

Sedermera as financial advisor in connection with the rights issue, VP Securities is the issuing agent and Nordic Issuing is the Company's settlement agent. Sedermera's visiting address is Norra Vallgatan 64, 211 22 Malmö, Sweden, VP Securities visiting address is Nicolai Eigtveds Gade 8, 1402 Copenhagen, and Nordic Issuing's visiting address is Stortorget 3, 211 22 Malmö, Sweden.

For full terms of the offer, see the prospectus drawn up in connection with the rights issue.

